Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1989
Abstract: Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)‐inhibitors indicated for the treatment of ALK‐positive metastatic non‐small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high. The aim of… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; crizotinib; crizotinib alectinib ... See more keywords
Sequential Therapy with Crizotinib and Alectinib in ALK‐Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.07.022
Abstract: Introduction: Alectinib and crizotinib have been approved for the therapy of NSCLC caused by anaplastic lymphoma kinase gene (ALK) rearrangement. The effect of alectinib or crizotinib on overall survival (OS) in patients with ALK‐rearranged NSCLC… read more here.
Keywords: alectinib crizotinib; crizotinib; treated group; crizotinib alectinib ... See more keywords